ASX ANNOUNCEMENT

Study on Efficacy of L-Dex® in Routine Clinical Practice Published

Brisbane, Australia and Carlsbad, Calif. 14 September, 2016 - ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announced that a new study published in the journal Frontiers in Oncology demonstrates the impact L-Dex® can have on patients at-risk for breast cancer related lymphoedema (BCRL).

The retrospective study, conducted by two surgical oncologists, Alison Laidley, MD of Texas Breast Specialists of Dallas, Texas and Beth Anglin, MD of North Texas Surgical Oncology in Plano, Texas, followed 326 patients with a median follow-up time of 21.7 months. The patients had undergone either an axillary lymph node dissection (ALND) or a sentinel lymph node biopsy (SLNB).

All patients had a pre-operative baseline measure and at least 2 follow-up visits post-operatively. Patients were surveilled with L-Dex measurements as part of their routine post-operative follow-up. The cumulative incidence of sub-clinical lymphoedema was 4.3% for the SLNB patients and 26.7% for ALND patients. L-Dex allowed for early intervention for these patients resulting in a reduction of persistent, clinical lymphoedema by 99.5% and 91.4%, respectively.

The study concluded; “The results of this retrospective study demonstrate that L-Dex assessments can be incorporated into routine breast cancer programs as part of follow-up. This is critically important given the recent changes in the NCCN survivorship guidelines for post-treatment follow-up care for breast cancer patients establishing that health-care providers “educate, monitor, and refer for lymphedema management”.

“As we await the results of the post-approval L-Dex study currently underway, we are pleased at the publication of these important and positive clinical data for L-Dex,” said Richard Carreon, Managing Director and Chief Executive Office of ImpediMed.

Richard Carreon
Managing Director & CEO

For further information, contact:
Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Media Contacts:

In Australia:
Kyahn Williamson, Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au
In the US:
Paul Maccabee/Andy Pollen, Maccabee PR
T: +1 612-337-0087
E: paul@maccabee.com; andy@maccabee.com

About ImpediMed
Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men. For additional information, visit www.impedimed.com.